Pliant Therapeutics, Inc. (PLRX)
- Zacks
5 Biotech Stocks Likely to Outpace Q2 Earnings Estimates
Let us look at some drug/biotech stocks, ABSI, AXLA, FRLN, DICE and PLRX, which are poised to beat on second-quarter earnings.
- Zacks
Pliant Therapeutics, Inc. (PLRX) Reports Q2 Loss, Tops Revenue Estimates
Pliant Therapeutics, Inc. (PLRX) delivered earnings and revenue surprises of 0% and 269.56%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results
SOUTH SAN FRANCISCO, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today provided a corporate update and reported second quarter 2022 financial results. “A highlight to our team’s progress in 2022 is the positive safety and efficacy data from the INTEGRIS-IPF Phase 2a trial. The trial met its primary endpoint demonstrating that PLN-7
